The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections
Abstract
BACKGROUND: Dalbavancin, a novel lipoglycopeptide with a pharmacokinetic profile that allows weekly dosing, is active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The efficacy of dalbavancin for treatment of skin and skin structure infections (SSSIs) was demonstrated in a phase 2 study. METHODS: In a phase 3 noninferiority study, patients with complicated SSSIs, including infections known or suspected to involve MRSA, were randomized (ratio, 2 : 1) in a double-blind manner to receive dalbavancin (1000 mg given intravenously on day 1 and 500 mg given intravenously on day 8) or linezolid (600 mg given intravenously or intravenously/orally every 12 h for 14 days). Efficacy was assessed by determining clinical and microbiological responses at the end of therapy and at the test-of-cure visit. Relapses were identified by additional follow-up approximately 1 month later. RESULTS: MRSA was identified in 51% of patients from whom a pathogen was isolated at baseline. Dalbavancin and linezolid demonstrated comparable clinical efficacy in the clinically evaluable population at the test-of-cure visit (88.9% and 91.2% success, respectively). The rate of clinical success at the end of therapy was >90% in both arms. Less than 1.0% of patients in either treatment arm experienced relapse after the test-of-cure visit. Both treatments yielded successful microbiological response in excess of 85% among microbiologically evaluable patients at end of therapy and at the test-of-cure visit for all pathogens combined, for all S. aureus strains, and for MRSA. Gastrointestinal symptoms were among the most common adverse events in both arms. A higher proportion of patients in the linezolid arm reported adverse events that were judged by the investigator to be probably/possibly related to treatment (dalbavancin arm, 25.4% of subjects; linezolid arm, 32.2% of subjects). CONCLUSIONS: Two doses of dalbavancin (1000 mg given on day 1 followed by 500 mg given on day 8) were as well tolerated and as effective as linezolid given twice daily for 14 days for the treatment of patients with complicated SSSI, including those infected with MRSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
The Changing Epidemiology of Staphylococcus aureus?
Chambers, H. F. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010204 · Cited by 1,495
Methicillin-Resistant Staphylococcus aureus
Brumfitt, W., & Hamilton-Miller, J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198905043201806 · Cited by 934
Engemann, J. J., Carmeli, Y., Cosgrove, S. E., Fowler, V. G., Bronstein, M. Z., Trivette, S. L., Briggs, J. P., Sexton, D. J., & Kaye, K. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367653 · Cited by 934
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Gorak, E. J., Yamada, S. M., & Brown, J. D. (1999) · Clinical Infectious Diseases · doi:10.1086/520437 · Cited by 332
Linezolid: A Review of its Use in the Management of Serious Gram-Positive Infections
Perry, C. M., & Jarvis, B. (2001) · Drugs · doi:10.2165/00003495-200161040-00008 · Cited by 275
Stevens, D. L., Smith, L. G., Bruss, J. B., McConnell-Martin, M. A., Duvall, S. E., Todd, W. M., & Hafkin, B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3408-3413.2000 · Cited by 242
Seltzer, E., Dorr, M. B., Goldstein, B. P., Perry, M., Dowell, J. A., Henkel, T., & Dalbavancin Skin and Soft-Tissue Infection Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/379015 · Cited by 231
Self-citationCommunity-acquired Methicillin-resistant Staphylococcus aureus among Military Recruits
Zinderman, C. E., Conner, B., Malakooti, M. A., LaMar, J. E., Armstrong, A., & Bohnker, B. K. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1005.030604 · Cited by 226
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
Boucher, H. W., Wilcox, M., Talbot, G. H., Puttagunta, S., Das, A. F., & Dunne, M. W. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310480 · Cited by 432
New antibiotics for bad bugs: where are we?
Bassetti, M., Merelli, M., Temperoni, C., & Astilean, A. (2013) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-12-22 · Cited by 403
New Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin and Telavancin
Zhanel, G. G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Hoban, D. J., & Karlowsky, J. A. (2010) · Drugs · doi:10.2165/11534440-000000000-00000 · Cited by 352
Metadata
- Authors
- Jauregui, L. E., Babazadeh, S., Seltzer, E., Goldberg, L., Krievins, D., Frederick, M., Krause, D., Satilovs, I., Endzinas, Z., Breaux, J., & O'Riordan, W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-11-15
- Volume
- 41
- Issue
- 10
- Pages
- 1407-1415
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2134463868
- Cited by
- 312
- References
- 22
- FWCI
- 17.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections. https://app.cochat.ai/papers/10.1086/497271
- The paper
- Jauregui, L. E., Babazadeh, S., Seltzer, E., Goldberg, L., Krievins, D., Frederick, M., Krause, D., Satilovs, I., Endzinas, Z., Breaux, J., & O'Riordan, W. (2005). Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections. Clinical Infectious Diseases. https://doi.org/10.1086/497271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.